Keppra®

Europe

In Europe, Keppra® (levetiracetam) is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Keppra® is indicated as adjunctive therapy

• in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

In Europe, Keppra® is also available as 100 mg/mL concentrate for solution for infusion and is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Keppra® is indicated as adjunctive therapy

• in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
   

Prescribing information Europe

• SmPC Keppra® (EU). Sourced from www.ema.europa.eu

USA

Keppra® (levetiracetam) is indicated in the US:

• for the treatment of partial-onset seizures in patients 1 month of age and older.
• as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with Juvenile Myoclonic Epilepsy
• as adjunctive therapy for the treatment of Primary Generalized Tonic-Clonic seizures in patients 6 years of age and older with Idiopathic Generalized Epilepsy.

Keppra® (levetiracetam) injection, for intravenous use is indicated:

• for the treatment of partial-onset seizures in patients 1 month of age and older
• as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with Juvenile Myoclonic Epilepsy.
• as adjunctive therapy for the treatment of Primary Generalized Tonic-Clonic seizures in patients 6 years of age and older with Idiopathic Generalized Epilepsy.
  
  Keppra® injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.

Prescribing information USA

Keppra® US Prescribing Information - Tablets and Oral solution (March 2023)

Keppra® US Prescribing Information - Injection for intravenous use (September 2022)

Other countries

For availability of Keppra® in other countries, please consult our local websites.